IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2024
Aggregated presentation by day and by market
| Purchases of own shares from August 5th to August 7th, 2024 | ||||||
| Name of the Issuer | Identity code of the Issuer | Day of the transaction | Identity code of the financial instrument | Total daily volume (in number of shares) | Daily weighted average purchase price of the shares | Market (MIC Code) |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 9 021 | 103,0295 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 4 119 | 102,9704 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 727 | 102,9999 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 05/08/2024 | FR0010259150 | 989 | 103,0782 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 7 492 | 102,8158 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 2 387 | 102,8565 | CEUX |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 455 | 102,7316 | TQEX |
| IPSEN | 549300M6SGDPB4Z94P11 | 06/08/2024 | FR0010259150 | 634 | 102,6875 | AQEU |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2024 | FR0010259150 | 2 153 | 103,0974 | XPAR |
| IPSEN | 549300M6SGDPB4Z94P11 | 07/08/2024 | FR0010259150 | 1 000 | 103,1034 | CEUX |
| TOTAL | 28 977 | 102,9480 | ||||
Attachment
Ipsen – February 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen appoints Michelle C. Werner as EVP, President of North America
Update: Ipsen voluntarily withdraws Tazverik® (tazemetostat) in follicular lymphoma and epithelioid sarcoma
Ipsen S.A. publishes its 2025 Consolidated Financial Statements
Ipsen – January 2026 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen nominates Peter Guenter to its Board of Directors
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
Ipsen – December 2025 – Monthly information relative to the total number of voting rights and shares composing the share capital
Ipsen – Half year statement – 2025 12 31
Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)